ALK and non-small cell lung carcinoma: Furthermore, lorlatinib has demonstrated the ability to target multiple ALK mutations, including C1156Y, I1171 N/S, F1174C, L1196M, L1198F, G1202R, D1203N, E1210K, and G1269A, showcasing sensitivity in NSCLC patients, even those resistant to prior-generation ALK inhibitors.